CN101662950A - 用于促进骨发育的组合物和方法 - Google Patents
用于促进骨发育的组合物和方法 Download PDFInfo
- Publication number
- CN101662950A CN101662950A CN200880012712A CN200880012712A CN101662950A CN 101662950 A CN101662950 A CN 101662950A CN 200880012712 A CN200880012712 A CN 200880012712A CN 200880012712 A CN200880012712 A CN 200880012712A CN 101662950 A CN101662950 A CN 101662950A
- Authority
- CN
- China
- Prior art keywords
- composition
- animal
- bone
- aforementioned
- kitten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000014461 bone development Effects 0.000 title abstract description 10
- 230000001737 promoting effect Effects 0.000 title description 6
- 235000013305 food Nutrition 0.000 claims description 38
- 241000282326 Felis catus Species 0.000 claims description 36
- 210000000988 bone and bone Anatomy 0.000 claims description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 230000035935 pregnancy Effects 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 229960001231 choline Drugs 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 229960004203 carnitine Drugs 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 230000007472 neurodevelopment Effects 0.000 abstract description 2
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 54
- 230000012010 growth Effects 0.000 description 19
- 235000020776 essential amino acid Nutrition 0.000 description 12
- 239000003797 essential amino acid Substances 0.000 description 12
- 230000036541 health Effects 0.000 description 11
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 125000001931 aliphatic group Chemical group 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000474 nursing effect Effects 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 5
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229960003080 taurine Drugs 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 235000020774 essential nutrients Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 230000008416 bone turnover Effects 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- VEPOHXYIFQMVHW-PVJVQHJQSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2s,3s)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 VEPOHXYIFQMVHW-PVJVQHJQSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- -1 flavouring Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000014786 phosphorus Nutrition 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000017168 chlorine Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000009596 postnatal growth Effects 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开用于促进生长期动物的骨发育的组合物和方法。
Description
相关申请的交叉参考
[0001]本申请权利要求2007年2月22日提交的美国临时申请第60/891171号的优先权，其内容通过参照结合到本文中。
发明领域
[0002]本发明涉及用于在哺乳动物促进骨发育的组合物和方法。
发明背景
[0003]市售可得到的宠物食品例如猫粮(cat food)包括针对许多不同营养需要而专门配制的组合物。这些组合物包括例如设计用于不同繁育类型、体积和身体条件的配方。它们也包括针对动物的不同生命周期的阶段所需要的营养而设计的配方。尽管可获得这样的宠物配方食品，然而，仍需要开发针对动物健康的其它方面的配方食品和方法。
[0004]动物易遭受损伤，包括骨折和关节错位(dislocated joints)。动物也可发生退化性疾病，例如骨质疏松症和骨关节炎。因此，需要抑制这样损伤和退化性疾病的组合物和方法。
[0005]骨为代谢活性的，经历钙的不断吸收和再沉积作用。这需要破骨细胞(除去骨(吸收作用))和造骨细胞(替代它(沉积作用))的连续和协同作用。这通常称为“骨代谢回转(bone turnover)”。在正常骨中，在动物的骨骼生长后，矿物质沉积作用与矿物质吸收作用处于平衡状态；然而，在某些条件下，骨吸收作用超过了骨沉积作用，导致骨矿物质含量丢失。伴随骨吸收作用增加的高水平骨代谢回转可损害骨强度，导致骨结构稀释。这可导致骨微结构异常和骨矿化作用减少。动物通常由于它们年龄的增加而减少骨矿物质含量，导致骨质减少，并且这种骨矿物质含量丢失是骨质疏松症的主要原因，骨质疏松症可引起更大的骨折倾向。动物也可能易患骨矿物质含量丢失，其中这样的骨矿物质含量丢失与多种疾病和病症有关。延迟骨丢失或者帮助骨再钙化作用的食品和补充剂已经被开发。然而，仍然需要开发这样的组合物，包括在生长期动物中促进骨形成以在动物成熟期间避免这样病症的组合物。
[0006]本领域通常已知骨释出(bone desorption)伴随骨碱性磷酸酶(“BAP”)增加，因为钙和磷自骨中释放。使用多种物质可影响与骨维持和骨形成有关的基因表达，包括骨形态发生蛋白和基质金属蛋白酶。例如，使用用于骨形成的肉毒碱是已知的。然而，需要开发用于在动物中促进骨形成的其它组合物和方法。
发明概述
[0007]在某些方面，本发明涉及用于在动物中促进骨发育的组合物。
[0008]本发明包括组合物1.0，一种用于在动物中促进骨发育的宠物食品组合物，所述组合物包含：
约0.1％-约0.7％的EPA；
约50ppm-约200ppm锰；和
约0.5％-约1.6％甲硫氨酸。
[0009]本发明也包括以下组合物：
1.1 包含约0.1％-约0.7％DHA，例如约0.1％-约0.5％或0.6％，例如约0.2％、约0.3％或约0.4％的组合物1.0；
1.2包含约200-约1200IU/kg维生素E，例如约500IU/kg-约1100IU/kg，约700、约800、约900或约1000IU/kg的组合物1.0或1.1；
1.3包含约50-约500ppm维生素C，例如约100-400ppm维生素C，例如约150、约175、约200或约225ppm的任何上述组合物；
1.4包含约100ppm-约500ppm肉毒碱，例如约200、约300或约400ppm肉毒碱的任何上述组合物；
1.5包含约2.5g/1000kcal-约7g/1000kcal赖氨酸的任何上述组合物；
1.6包含约2400ppm-约7500ppm胆碱，例如约3000、约4000、约4500、约4600、约4625、约4650、约4700、约5000或约6000ppm胆碱的任何上述组合物；
1.7包含约0.1％-约0.6％EPA，例如约0.2％、约0.3％、约0.4％或约0.5％EPA的任何上述组合物；
1.8包含约50ppm-约150ppm锰的任何上述组合物；
1.9包含约0.8％-约1.6％甲硫氨酸，例如约1.3或约1.4％甲硫氨酸的任何上述组合物；
1.10任何上述组合物还包含：
0-约90％重量的碳水化合物；
约5％-约70％重量的蛋白质；
约2％-约50％重量的脂肪；
约0.1％-约20％重量的总膳食纤维；
0-约15％，或约2％-约8％重量的维生素、矿物质以及以不同百分比存在的支持动物营养需要的其它营养素。
1.11包含约5％-约55％重量的碳水化合物的组合物1.10；
1.12包含约20％-约60％重量的蛋白质，例如约30％-约55％的组合物1.10或1.11；
1.13包含约5％-约40％重量的脂肪，例如至少约8％或约9％-约40％脂肪的组合物1.10-1.12中的任何一种；
1.14包含约1％-约11％重量的总膳食纤维的组合物1.10-1.13中的任何一种；
1.15包含约1000-约4000ppm牛磺酸的任何上述组合物；
1.16包含约0.5％-约6.0％亚油酸，例如约2.5％-5％亚油酸的任何上述组合物；
1.17包含约1％-约3％总n-3脂肪酸，例如约1.3％、约1.4％、约1.5％或约1.6％总n-3脂肪酸的任何上述组合物。
1.18包含约1％-约6％总n-6脂肪酸，例如3％-5％，约3.5％或约4％脂肪酸的任何上述组合物。
[0010]本发明组合物可为湿的、干的或半固体食物。
[0011]本发明包括方法2.0，一种在猫科动物中促进骨发育和/或关节健康的方法，该方法包括给予猫科动物组合物1.0-1.18中的任何一种。
[0012]本发明也包括以下方法：
2.1方法2.0的方法，其中猫科动物为小猫。
2.2方法2.0或2.1的方法，其中猫科动物出生于在妊娠期间饲料组合物1.0-1.18中任何一种的母猫。
2.3方法2.2的方法，其中猫科动物在子宫内。
2.4方法2.2的方法，其中母猫在妊娠前饲料组合物1.0-1.18中的任何一种。
2.5方法2.2或2.4的方法，其中母猫在大部分妊娠期间饲料组合物1.0-1.18中的任何一种。
2.6方法2.2-2.5中的任何一种方法，其中母猫在妊娠前和妊娠期间喂给基本上由组合物1.0-1.18中的任何一种组成的组合物。
2.7上述方法中的任何一种方法，其中小猫在断奶前，例如在仍然护理的同时，饲料组合物1.0-1.18中的任何一种。
2.8上述方法中的任何一种方法，其中小猫在断奶后饲料组合物1.0-1.18中的任何一种。
2.9方法2.8的方法，其中小猫喂给由组合物1.0-1.18中任何一种组成的食物组合物。
2.10上述方法中的任何一种方法，其中有效量的组合物被给予所述动物。
2.11上述方法中的任何一种方法，其中所述组合物被给予所述动物持续有效量的时间。
通过参考以下实施例的详细描述，将理解本发明的其它特征和优点。
[0013]除了直接给予生长期动物例如生长期小狗或小猫在此公开的组合物以外，当动物仍在子宫内或动物在被护理时，也期待可将组合物给予雌亲动物。
[0014]通过参考以下实施例的详细描述，将理解本发明的其它特征和优点。
发明详述
[0015]期待在此描述的本发明不限于所描述的具体方法学、试验方案和试剂，因为这些可以变化。也应理解在此使用的术语仅用于描述具体实施方案的目的，并不打算以任何方式限制本发明的范围。
[0016]除非另外定义，在此使用的所有技术和科学术语具有与本发明所属领域的普通技术人员通常理解的相同含义。另外，在此引用的所有参考文献通过参照全部结合到本文中。即使在本公开和所引用参考文献中的定义有矛盾，也以本公开为准。
[0017]如在此和所附权利要求中使用的，单数形式“一”、“一个”和“该”包括复数意义，除非上下文另外明确地指明。
[0018]本发明涉及任何动物，优选地为哺乳动物，更优选地为陪伴动物。术语“陪伴动物”指生活与人密切相关的任何动物并且包括(但不限于)任何品种的犬和猫。然而，本文期待其饮食可由人控制的任何动物可从本文所公开的配方食物的喂养中得益。这些动物可包括例如饲养的农场动物(例如牛、马、猪等)以及关养例如在动物园等中的未驯化动物。优选地，动物为猫科动物，小猫或成年猫。
[0019]如在此使用的，达到特定效果的“有效的量”或“有效量”等术语指能有效达到特殊需要的生物学效果的如在此描述的化合物、物质或组合物的量。如在此期待的，这样的效果包括例如，当在子宫中发育时和/或在其出生后的生长阶段，例如，出生后不超过6个月、9个月、12个月或15个月期间，促进动物的神经发育、骨和关节健康、免疫功能和/或提高健康的身体组成。可例如通过当动物在子宫中或处于护理期时给予所述动物的雌亲本发明组合物以及通过在其生长阶段直接给予动物本发明组合物，达到这样的有效活性。
[0020]如在此使用的，在例如在此描述的生长期动物的特定生物学过程或身体状况的“提高”指与对照动物相比较，生长期动物的生物过程或身体状况的提高。本领域的技术人员可确定这样的过程或状况的提高。
[0021]如在此使用的，“促进生长期动物的发育”、“促进生长”或“促进生长”等术语指生长期动物的一个或更多个生物学过程和/或身体状况的总体改善，包括(但不限于)对生物生长和发育极为重要的生物学过程，所述生物过程包括(但不限于)在此描述的生物过程，例如骨和关节健康、神经和免疫系统发育及体重增加(例如瘦肉肌肉质量增加而不是脂肪组织)。
[0022]动物的“生长”生命阶段指从出生或断奶(约8周龄)至约1岁龄的时期。
[0023]如在此使用的，术语“小猫”指未成熟的猫，一般地年龄在出生与12个月之间。
[0024]如在此使用的“必需氨基酸”指不能被生物重新合成因而必须由膳食提供的那些氨基酸。本领域技术人员应该理解必需氨基酸在物种与物种之间各不相同，这取决于生物的代谢。例如，通常理解为对于狗和猫(及人)的必需氨基酸为苯丙氨酸、亮氨酸、甲硫氨酸、赖氨酸、异亮氨酸、缬氨酸、苏氨酸、色氨酸、组氨酸和精氨酸。另外，牛磺酸尽管学术上不是氨基酸，却是半胱氨酸的衍生物，被认为对猫是必需的。均衡膳食可提供所有的必需氨基酸，然而，存在某些更关键的必需氨基酸，因为缺乏它们中的一种的膳食将限制其它种氨基酸的有用性，即使其它必需氨基酸以足够的量存在。
[0025]如由本领域技术人员理解的，“限制氨基酸”指如果膳食中存在量不足会导致限制其它必需氨基酸的有用性的氨基酸，即使其它必需氨基酸以足够大的量存在。赖氨酸为在此公开的组合物中的限制必需氨基酸。因此，剩余的必需氨基酸被定量配制或与对影响所需生物学效果关键的确定的赖氨酸量维持“平衡”关系。如在此使用的，“平衡氨基酸(balanced amino acids)”指以确保最佳动物生长和发育的必需氨基酸赖氨酸与能量的关系。
[0026]如在此使用的“必需营养素”指不能由身体合成的正常身体功能需要的营养素。必需营养素的种类包括维生素、膳食矿物质、必需脂肪酸和必需氨基酸。本领域技术人员应该理解，营养素被认为取决于生物的代谢而在物种与物种之间基本是变化的。例如，对于狗和猫的必需营养素包括维生素A、D、E、K、B1、B6、B12、核黄素、烟酸、泛酸、叶酸、钙、磷、镁、钠、钾、氯、铁、铜、锌、锰、硒和碘。胆碱，通常看作是B族复合维生素，可包含在半必需营养素中。
[0027]肉毒碱，也称为L-肉毒碱(左卡尼汀)，为自氨基酸赖氨酸和甲硫氨酸合成的季铵化合物并负责将脂肪酸从细胞溶胶输送进入线粒体。
[0028]不受任何理论或特定作用模式的限制，本发明基于惊人的发现，即向宠物食品组合物加入某些成分并给予动物这些组合物可促进生长期动物的骨发育/健康和/或关节健康。数据表明，喂给本发明组合物的动物(或其雌亲在妊娠期间和断奶前饲料组合物，但是在其幼子的整个生长期继续喂给的那些动物)证实减少了BAP和脱氧吡啶啉(deoxypyridinoline)的水平。因此，在一个方面，本发明涉及在动物中促进骨发育的方法，该方法包括给予所述动物本发明组合物。增加的骨发育可通过减少的BAP或脱氧吡啶啉水平得到证明。因此，在另一个方面，本发明涉及在动物中减少BAP和/或脱氧吡啶啉水平的方法，该方法包括给予动物本发明组合物。
[0029]I型胶原组织为动物体内最丰富的胶原类型之一，并且是于矿化骨(mineralized bone)中发现的唯一胶原类型，其构成有机基质的90％以上。另外，I型胶原与其它胶原类型一起存在于结缔组织例如关节中。I型胶原的羧基端交联端肽(“ICTP”)为I型胶原的羧基端端肽(tehopeptide)区。肽来源于骨吸收和结缔组织的降解。确信增加的ICTP的血清浓度表示骨或关节物质丢失。因此，在一个方面，本发明涉及在动物中促进健康骨和关节的方法，该方法包括给予所述动物本发明的组合物。在另一个方面，本发明涉及在动物中减少ICTP，例如血清水平的方法，该方法包括给予动物本发明的组合物。
[0030]如在此期待的，本发明的组合物包含营养完全和平衡的动物饲料组合物。这样的组合物连同其它营养素和组分一起，还包含推荐的健康量的蛋白质、碳水化合物和脂肪。“营养完全和平衡的动物饲料组合物”以及适合于动物饲料组合物的营养素和组分及其所推荐的量是本领域技术人员熟悉的(参见例如，国立研究院，2006狗和猫的营养需求，国家学术出版社(National Academy Press)，Washington D.C.或美国饲料质量委员会的正式出版物(the Official Publication of theAssociation of American Feed Control Officials，Inc.狗和猫的营养需求2006)。
[0031]在此期待本文公开的组合物也可包含以本领域技术人员熟悉的量和组合存在的抗氧剂、添加剂、稳定剂、增稠剂、矫味剂、增味剂和着色剂。“抗氧剂”指能够与自由基反应或减少自由基产生并中和它们的物质。实例包括(但不限于)β-胡萝卜素、硒、辅酶Q10(泛醌)、黄体素、生育三烯酚、大豆异黄酮、S-腺苷甲硫氨酸、谷胱甘肽、牛磺酸、N-乙酰半胱氨酸、维生素E、维生素D、维生素C、类黄酮(flavanoids)、花色素和硫辛酸。
[0032]尽管期待任何稠度(consistency)或水分含量的食物，优选地本发明的组合物可为例如湿的、半干或干的动物食物组合物。“湿的”食物指以罐或箔袋形式出售并具有约70％-90％水分含量的组合物。“干的”食物指具有约5％-15％水分含量并通常以小片或粗粒形式制备的组合物。半干组合物指具有约15％-70％水分的组合物。在此也期待适中水分稠度的组合物和可包含具有不同稠度的组分以及可包含多于一种稠度的组分的组合物，例如软的，耐嚼的肉样颗粒以及具有外层谷物组分和内层乳脂组分的粗粒的那些组合物。在此也期待如在例如美国专利6,517,877中描述的适中水分稠度的组合物和可包含具有不同稠度的组分以及可包含多于一种稠度的组分例如软的，耐嚼的肉样颗粒以及具有外层谷物组分和内层乳脂组分的粗粒的那些组合物。
[0033]以下实施例进一步阐明本发明并且不打算限制本发明。如全文所使用的，范围被用做描述该范围内每一个和各个值的简写。所述范围内的任何值可选作范围的端值。应该理解当描述配方食物时，它们可如本领域常见的那样，根据其组分进行描述，尽管在实际配方中的这些组分可在其制备、贮存和使用时相互反应，并且这样的产物打算包含在所描述的配方食品中。
[0034]以下实施例进一步描述和证实本发明范围内的例证性实施方案。给出实施例仅用于阐明并不构成对本发明的限制，因为许多变化是可能的而不背离其精神和范围。除了在此显示和描述的那些以外，本发明的多种修饰对本领域技术人员应是显而易见的并且打算落入所附的权利要求书的范围内。
实施例1
[0035]促进生长期动物发育的配方食品在以下得到公开。开发这些组合物考虑到“理想蛋白质概念”(Baker和Czarnecki-Maulden，1991Annu.Rev.Nutr.11：239-63)。
[0036]食物被开发用于“生长”生命阶段。这些食物包括用于犬生长和猫生长的配方食品。关于这些食物的最小营养素推荐值以及原型食物(prototype food)的目标值列于以下表1中。
表1：小猫配方食品的主要营养素
| 营养素 | 目标值 | 最小值 | 最大值 |
| 蛋白质，％ | 45.5 | 30 | 55 |
| 甲硫氨酸，％ | 1.4 | 0.8 | 1.5 |
| 锰，ppm | 90 | 50 | 200 |
| DHA，％ | 0.21 | 0.1 | 0.5 |
| EPA，％ | 0.31 | 0.1 | 0.7 |
| 胆碱，ppm | 4880 | 2500 | 7500 |
| 牛磺酸，ppm | 2380 | 1000 | 4000 |
| 亚油酸，％ | 3.8 | 2.5 | 6 |
| 总n-3脂肪酸，％ | 1.35 | 1 | 3 |
| 维生素E，IU/kg | 900 | 200 | 1200 |
| 维生素C，ppm | 90 | 50 | 500 |
| 赖氨酸，g/1000kcal | 4 | 2.5 | 7 |
实施例2
[0037]四种食品用于研究，实验配方X、商品A、商品A1和商品B。各食品成分显示于表2中。商品A、A1和B食品从商业来源得到。商品A和A1是相同品牌的食品，但生产于不同的批次。
表2：喂给母猫和小猫的食品营养素分析
| 营养素 | 配方X | 市售A | 市售A1 | 市售B |
| 粗蛋白，％ | 41.63 | 41.2 | 36.09 | 35.47 |
| 脂肪，％ | 23.15 | 14.47 | 12.43 | 22.94 |
| Ca，％ | 1.23 | 1.12 | 1.50 | 1.06 |
| P，％ | 1.11 | 1.11 | 1.19 | 0.96 |
| DHA，％ | 0.22 | 0.06 | 0.04 | ＜0.01 |
| EPA，％ | 0.32 | 0.06 | 0.04 | ＜0.01 |
| 亚油酸，％ | 3.79 | 1.59 | 1.96 | 1.37 |
| 总n-3脂肪酸，％ | 1.47 | 0.34 | 0.25 | 0.53 |
| 总n-6脂肪酸，％ | 3.86 | 1.88 | 1.91 | 1.44 |
| 牛磺酸，％ | 0.24 | 0.17 | 0.23 | 0.20 |
| 甲硫氨酸，％ | 1.3 | 0.76 | 0.62 | 0.99 |
| 胱氨酸，％ | 0.49 | 0.51 | 0.44 | 0.35 |
| 锰，ppm | 78 | 63 | 77 | 56 |
| 维生素E，IU/kg | 914 | 35 | 76 | 138 |
| 维生素C，ppm | 183 | - | - | - |
| 胆碱，ppm | 4624 | 3010 | 2807 | 3331 |
[0038]19只母猫在妊娠前喂给配方食品X或商品A至少2周。母猫保持群体生活在笼舍中，直到经触诊确认有孕，然后被转移到产房。自喂给商品A的母猫产下48只小猫和自喂给配方食品X的母猫产下16只小猫。在小猫出生后，产自母猫的小猫继续喂给相同食物直到小猫断奶。
[0039]在断奶后，将产自喂给商品A的母猫的48只小猫被如下分组：16只小猫喂给商品A1；16只小猫喂给商品B；和16只小猫喂给配方食品X。在断奶后，产自喂给配方食品X的母猫的16只小猫保持喂给配方食品X。
[0040]在断奶前，在3、6和9个月龄时，自小猫采取血清样品并保持冷冻直到使用。然后解冻样品并如先前在Yamka等，INTERN JAPPL RES VET MED，第4卷，第3期，2006中所述进行试验，和如在表12中呈现的那样进行商品试验。
表12商品试验
| 试剂盒 | 卖主 | 目录号 |
| Metra BAP EIA | Quidel(San Diego，CA) | 8012 |
| Metra总Dpd EIA | Quidel(San Diego，CA) | 8032 |
| UniQ ICTP EIA | Immunodiagnostic Systems，Inc.(Fountain Hills，AZ) | OD-06099 |
[0041]对断奶前的小猫，数据经双尾(2 tailed)t-检验分析显示在产自喂给配方食品X的母猫的小猫(其中小猫也喂养配方食品X)具有显著更低浓度的C端交联端肽(P＝0.014)和更低浓度(P＝0.051)的BAP。
[0042]骨碱性磷酸酶-整体方差分析(Bone Alkaline Phosphatase-GlobalANOVA)显示在3个月龄而不是6或9个月龄的时间点具有显著性差异。在市售A-市售A1小猫和配方X-配方X小猫组之间进行比较，经t-检验进一步分析数据显示在配方X-配方X组中，于所有时间点具有显著更低的BAP活性。
[0043]I型软骨的羧基端c-端肽(ICTP)-Global ANOVA分析显示，各组均值之间在除9个月龄以外的所有时间点均有显著差异。分析来自配方食品A喂给雌亲的3个小猫组，显示仅在3个月龄时各均值之间有显著差异。经t-检验比较配方X-配方X喂养组与商品A-商品A1喂养组，显示对配方食品X-配方食品X组在除于6个月(在6个月时P＝0.054)外测量的所有时间点具有显著更低的值。
[0044]脱氧吡啶啉(Deoxy-pyrodiniline)(DPD)-整体方差分析(GlobalANOVA)分析显示在3、6和9个月龄时的均值之间的显著差异。分析得自仅喂给配方食品A的雌亲的3个小猫组得到相同结果。在配方X-配方X小猫与商品A-商品A1小猫之间的单一t-检验比较显示对配方X-配方X组在3和6个月龄时具有显著差异，在那两个时间点具有更低的值。
Claims (20)
1.一种宠物食品组合物，所述组合物包含：
约0.1％-约0.7％的EPA；
约50ppm-约200ppm锰；和
约0.5％-1.6％甲硫氨酸。
2.权利要求1的组合物，所述组合物包含约0.1％-约0.7％的DHA。
3.权利要求1或2的组合物，所述组合物包含约200-约1200IU/kg的维生素E。
4.前述权利要求中任何一项的组合物，所述组合物包含约50-约500ppm维生素C。
5.前述权利要求中任何一项的组合物，所述组合物包含约100ppm-约500ppm肉毒碱。
6.前述权利要求中任何一项的组合物，所述组合物包含约2.5g/1000kcal-约7g/1000kcal赖氨酸。
7.前述权利要求中任何一项的组合物，所述组合物包含约2400ppm-约7500ppm胆碱。
8.前述权利要求中任何一项的组合物，所述组合物包含约0.1％-约0.6％EPA。
9.前述权利要求中任何一项的组合物，所述组合物包含约50ppm-约150ppm锰。
10.前述权利要求中任何一项的组合物，所述组合物包含约0.8％-约1.6％甲硫氨酸。
11.一种促进猫科动物的骨形成的方法，该方法包括给予所述猫科动物权利要求1-10中任何一项的组合物。
12.权利要求11的方法，其中所述猫科动物为小猫。
13.权利要求11或12的方法，其中所述猫科动物出生于喂给权利要求1-10中任何一项的组合物的母猫。
14.权利要求13的方法，其中所述猫科动物在子宫内。
15.权利要求13-14中任何一项的方法，其中所述母猫在妊娠前喂给权利要求1-10中任何一项的组合物。
16.权利要求13-15中任何一项的方法，其中所述母猫在大部分妊娠期间喂给权利要求1-10中任何一项的组合物。
17.权利要求13-16中任何一项的方法，其中所述母猫在妊娠前和妊娠期间喂给基本上由权利要求1-10中任何一项的任何一种组合物组成的组合物。
18.权利要求11-17中任何一项的方法，其中小猫在断奶前喂给权利要求1-10中任何一项的组合物。
19.权利要求11-18中任何一项的方法，其中小猫在断奶后喂给权利要求1-10中任何一项的组合物。
20.一种通过抑制骨碱性磷酸酶促进骨形成的方法，该方法包括给予哺乳动物权利要求1-10中任何一项的组合物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89117107P | 2007-02-22 | 2007-02-22 | |
| US60/891,171 | 2007-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101662950A true CN101662950A (zh) | 2010-03-03 |
Family
ID=39563552
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880013110.4A Expired - Fee Related CN101686712B (zh) | 2007-02-22 | 2008-02-22 | 增进成长中的动物的发育的组合物和方法 |
| CN200880012712A Pending CN101662950A (zh) | 2007-02-22 | 2008-02-22 | 用于促进骨发育的组合物和方法 |
| CN2008800125423A Expired - Fee Related CN101662949B (zh) | 2007-02-22 | 2008-02-22 | 促进神经发育的组合物和方法 |
| CN201410643425.4A Pending CN104472871A (zh) | 2007-02-22 | 2008-02-22 | 增强猫科动物的免疫系统的组合物和方法 |
| CN200880012994A Pending CN101686711A (zh) | 2007-02-22 | 2008-02-22 | 增强猫科动物的免疫系统的组合物和方法 |
| CN200880012951A Pending CN101662951A (zh) | 2007-02-22 | 2008-02-22 | 用于改变基因表达的组合物和方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880013110.4A Expired - Fee Related CN101686712B (zh) | 2007-02-22 | 2008-02-22 | 增进成长中的动物的发育的组合物和方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800125423A Expired - Fee Related CN101662949B (zh) | 2007-02-22 | 2008-02-22 | 促进神经发育的组合物和方法 |
| CN201410643425.4A Pending CN104472871A (zh) | 2007-02-22 | 2008-02-22 | 增强猫科动物的免疫系统的组合物和方法 |
| CN200880012994A Pending CN101686711A (zh) | 2007-02-22 | 2008-02-22 | 增强猫科动物的免疫系统的组合物和方法 |
| CN200880012951A Pending CN101662951A (zh) | 2007-02-22 | 2008-02-22 | 用于改变基因表达的组合物和方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US20100137404A1 (zh) |
| EP (5) | EP2129237B1 (zh) |
| JP (5) | JP5285625B2 (zh) |
| CN (6) | CN101686712B (zh) |
| AU (5) | AU2008218195C1 (zh) |
| BR (5) | BRPI0807373A2 (zh) |
| CA (5) | CA2678938C (zh) |
| DK (1) | DK2129237T3 (zh) |
| ES (1) | ES2546284T3 (zh) |
| RU (5) | RU2435435C2 (zh) |
| WO (5) | WO2008103956A1 (zh) |
| ZA (5) | ZA200906390B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103315187A (zh) * | 2013-07-17 | 2013-09-25 | 江苏桂龙生物技术有限公司 | 一种预防宠物骨骼性疾病的饲料 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1937721T3 (pl) * | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
| WO2008103956A1 (en) * | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for promoting bone development |
| CN102316865B (zh) * | 2008-12-12 | 2017-04-19 | 科耐特有限公司 | 用于改善正常的认知功能的l‑赖氨酸 |
| DK2493491T3 (da) | 2009-12-29 | 2014-06-30 | Hills Pet Nutrition Inc | Sammensætninger, indeholdende ingefær til lindringen eller forebyggelsen af inflammatoriske tilstande hos katte og hunde |
| RU2012153677A (ru) * | 2010-05-12 | 2014-06-20 | Хилл'С Пет Ньютришн, Инк. | Способы диагностики, контроля и профилактики воспаления и облегчения воспалительных состояний у кошачьих |
| US20130273196A1 (en) * | 2010-12-20 | 2013-10-17 | Hill's Pet Nutrition, Inc | Pet Food Compositions for Inducing a Satiety Response |
| JP5983601B2 (ja) * | 2011-04-13 | 2016-08-31 | 味の素株式会社 | 栄養組成物 |
| US8828426B2 (en) | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
| WO2013095935A1 (en) | 2011-12-19 | 2013-06-27 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating hyperthyroidism in companion animals |
| CN104026401B (zh) * | 2014-06-10 | 2016-04-27 | 务川县绿之源农业技术推广中心 | 一种小型幼犬粮 |
| EP3213640B1 (en) * | 2014-10-30 | 2021-07-21 | Fuji Oil Holdings Inc. | Long-chain polyunsaturated fatty-acid-containing fat and food containing same |
| GB201522300D0 (en) * | 2015-12-17 | 2016-02-03 | Mars Inc | Puppy growth food product |
| AU2017376984B2 (en) | 2016-12-15 | 2021-12-23 | Société des Produits Nestlé S.A. | Compositions and methods for small canines |
| EP3554256B1 (en) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
| US11813238B2 (en) * | 2017-05-29 | 2023-11-14 | Societe Des Produits Nestle S.A. | Medium chain fatty acids for use in the prevention or treatment of cardiac enlargement and/or valvular heart disease |
| US20190240180A1 (en) * | 2018-02-08 | 2019-08-08 | Nestec Sa | Mct-based nutrition blend for providing health benefits in companion animals |
| CN108244374A (zh) * | 2018-02-27 | 2018-07-06 | 佛山市雷米高动物营养保健科技有限公司 | 猫用营养粉剂及其制备方法 |
| KR20210120091A (ko) * | 2019-02-01 | 2021-10-06 | 마아즈, 인코오포레이티드 | 고양잇과 동물용 사료 조성물 |
| CN110537630A (zh) * | 2019-09-09 | 2019-12-06 | 天津农学院 | 1，2二硫戊环-3-戊酸的应用、幼犬鲜粮和延长幼犬鲜粮贮藏期的方法 |
| AU2020410289A1 (en) * | 2019-12-19 | 2022-05-26 | Societe Des Produits Nestle Sa | Compositions and methods for providing a health benefit to a growing animal |
| EP4202564A1 (fr) | 2021-12-22 | 2023-06-28 | The Swatch Group Research and Development Ltd | Mouvement mecanique horloger comprenant un balancier pivote magnetiquement |
| WO2023150389A1 (en) * | 2022-02-07 | 2023-08-10 | Cornell University | Compositions and methods for increasing dha availability |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267195A (en) * | 1976-09-10 | 1981-05-12 | University Of Texas | Dog food flavors |
| US4130651A (en) * | 1978-03-31 | 1978-12-19 | American Cyanamid Company | Butamisole injectable formulations having improved margin of safety in dogs |
| JPH0625057B2 (ja) | 1987-12-14 | 1994-04-06 | 日本油脂株式会社 | 骨形成促進剤 |
| JPH04166039A (ja) * | 1990-10-26 | 1992-06-11 | Hirotoshi Yokura | ペットフード |
| US5690988A (en) * | 1996-02-02 | 1997-11-25 | Colgate Palmolive Company | Pet food composition of improved palatability and a method of enhancing the palatability of a food composition |
| US5851573A (en) * | 1997-04-29 | 1998-12-22 | The Iams Company | Pet food composition for large breed puppies and method for promoting proper skeletal growth |
| US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
| GB2367489B (en) * | 2000-07-31 | 2005-02-09 | Mars Inc | Use of antioxidants |
| NZ527924A (en) | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
| US6071544A (en) * | 1999-04-01 | 2000-06-06 | The Iams Company | Dietary compositions and method for promoting healthy weight loss cats |
| IL146438A0 (en) * | 1999-05-27 | 2002-07-25 | Iams Company | Process and product for enhancing immune response in companion animal using a combination of antioxidants |
| EG22407A (en) * | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
| GB2367487A (en) | 2000-10-04 | 2002-04-10 | John Kennedy Mcmillan | Tooth cleaner |
| ATE402615T1 (de) | 2000-12-29 | 2008-08-15 | Martin Francis Gannon | Tiernahrungsmittelzusammensetzung |
| US6582752B2 (en) * | 2001-11-02 | 2003-06-24 | Nestec, Ltd | Methods and compositions for a gender specific diet for puppies |
| WO2004006688A1 (en) | 2002-07-12 | 2004-01-22 | The Iams Company | Synergistic effect of diet and human interaction on the behavior of dogs |
| WO2004008196A1 (ja) * | 2002-07-13 | 2004-01-22 | Autocloning Technology Ltd. | 偏光解析装置 |
| EP1524912A1 (en) | 2002-07-26 | 2005-04-27 | DSM IP Assets B.V. | Compositions comprising lactoferrin |
| US20070082008A1 (en) | 2003-03-07 | 2007-04-12 | Advanced Bionutrition Corporation | Feed formulation for terrestrial and aquatic animals |
| WO2004095940A1 (en) | 2003-04-25 | 2004-11-11 | The University Of Newcastle | Biomass containing animal feed |
| WO2005006877A1 (en) * | 2003-07-03 | 2005-01-27 | Hill's Pet Nutrition, Inc. | Compositions and methods for decreasing age-related deterioration in metal activities in companion animals |
| RU2358440C2 (ru) | 2003-07-07 | 2009-06-20 | Хилл`С Пет Ньютришн, Инк. | Композиция для улучшенного окислительного статуса домашних животных |
| US8128956B2 (en) * | 2003-09-12 | 2012-03-06 | Mars, Inc. | Food product for hairball treatment |
| US8921422B2 (en) * | 2003-10-01 | 2014-12-30 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
| US20050266051A1 (en) | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
| AU2005280008B2 (en) * | 2004-08-30 | 2011-06-16 | Hill's Pet Nutrition, Inc. | Genome-based diet design |
| CN1631207A (zh) | 2004-12-03 | 2005-06-29 | 王志文 | 能改善猫狗皮毛质量的不饱和脂肪酸饲料添加剂及饲料 |
| CA2592827C (en) | 2004-12-30 | 2013-08-13 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a growing animal |
| US8148325B2 (en) | 2004-12-30 | 2012-04-03 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| EP1928552A2 (en) * | 2005-09-30 | 2008-06-11 | Nestec S.A. | Methods and compositions for improving cognitive function |
| WO2007082231A1 (en) * | 2006-01-10 | 2007-07-19 | Hill's Pet Nutrition, Inc. | Compositions and method for promoting fat loss |
| JP2009545308A (ja) * | 2006-08-09 | 2009-12-24 | ザ アイムス カンパニー | 骨の健康及び筋肉の健康を改善する方法 |
| WO2008103956A1 (en) | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for promoting bone development |
-
2008
- 2008-02-22 WO PCT/US2008/054796 patent/WO2008103956A1/en active Application Filing
- 2008-02-22 US US12/528,362 patent/US20100137404A1/en not_active Abandoned
- 2008-02-22 BR BRPI0807373-2A patent/BRPI0807373A2/pt active Search and Examination
- 2008-02-22 JP JP2009551045A patent/JP5285625B2/ja active Active
- 2008-02-22 WO PCT/US2008/054786 patent/WO2008118586A1/en active Application Filing
- 2008-02-22 CN CN200880013110.4A patent/CN101686712B/zh not_active Expired - Fee Related
- 2008-02-22 US US12/528,137 patent/US20110059202A1/en not_active Abandoned
- 2008-02-22 BR BRPI0807372-4A patent/BRPI0807372A2/pt not_active Application Discontinuation
- 2008-02-22 RU RU2009135263/13A patent/RU2435435C2/ru not_active IP Right Cessation
- 2008-02-22 WO PCT/US2008/054773 patent/WO2008103939A1/en active Application Filing
- 2008-02-22 RU RU2009135260/15A patent/RU2441394C2/ru not_active IP Right Cessation
- 2008-02-22 BR BRPI0807789-4A2A patent/BRPI0807789A2/pt active Search and Examination
- 2008-02-22 AU AU2008218195A patent/AU2008218195C1/en not_active Ceased
- 2008-02-22 WO PCT/US2008/054800 patent/WO2008103958A1/en active Application Filing
- 2008-02-22 US US12/528,164 patent/US9888709B2/en active Active
- 2008-02-22 CA CA2678938A patent/CA2678938C/en active Active
- 2008-02-22 AU AU2008218193A patent/AU2008218193B2/en not_active Ceased
- 2008-02-22 CN CN200880012712A patent/CN101662950A/zh active Pending
- 2008-02-22 WO PCT/US2008/054789 patent/WO2008103950A1/en active Application Filing
- 2008-02-22 BR BRPI0807691A patent/BRPI0807691A2/pt not_active Application Discontinuation
- 2008-02-22 US US12/528,153 patent/US20100104599A1/en not_active Abandoned
- 2008-02-22 ES ES08730572.8T patent/ES2546284T3/es active Active
- 2008-02-22 EP EP08730572.8A patent/EP2129237B1/en not_active Not-in-force
- 2008-02-22 CA CA2679065A patent/CA2679065C/en not_active Expired - Fee Related
- 2008-02-22 CN CN2008800125423A patent/CN101662949B/zh not_active Expired - Fee Related
- 2008-02-22 AU AU2008218187A patent/AU2008218187C1/en not_active Ceased
- 2008-02-22 EP EP08730556.1A patent/EP2112889B1/en not_active Not-in-force
- 2008-02-22 DK DK08730572.8T patent/DK2129237T3/en active
- 2008-02-22 CA CA2679215A patent/CA2679215C/en not_active Expired - Fee Related
- 2008-02-22 US US12/528,158 patent/US20100143497A1/en not_active Abandoned
- 2008-02-22 RU RU2009135261/13A patent/RU2427278C2/ru not_active IP Right Cessation
- 2008-02-22 EP EP08730573.6A patent/EP2124611B1/en not_active Not-in-force
- 2008-02-22 JP JP2009551047A patent/JP5286287B2/ja not_active Expired - Fee Related
- 2008-02-22 JP JP2009551049A patent/JP5474571B2/ja active Active
- 2008-02-22 RU RU2009135245/13A patent/RU2412611C1/ru not_active IP Right Cessation
- 2008-02-22 RU RU2009135231/13A patent/RU2436410C2/ru not_active IP Right Cessation
- 2008-02-22 AU AU2008231241A patent/AU2008231241B2/en not_active Ceased
- 2008-02-22 EP EP08780443A patent/EP2124610A1/en not_active Ceased
- 2008-02-22 EP EP08743532.7A patent/EP2124612B1/en active Active
- 2008-02-22 AU AU2008218176A patent/AU2008218176B2/en not_active Ceased
- 2008-02-22 CA CA2679008A patent/CA2679008C/en not_active Expired - Fee Related
- 2008-02-22 JP JP2009551040A patent/JP5474570B2/ja active Active
- 2008-02-22 CN CN201410643425.4A patent/CN104472871A/zh active Pending
- 2008-02-22 CN CN200880012994A patent/CN101686711A/zh active Pending
- 2008-02-22 JP JP2009551043A patent/JP5286286B2/ja not_active Expired - Fee Related
- 2008-02-22 CA CA2679682A patent/CA2679682C/en not_active Expired - Fee Related
- 2008-02-22 BR BRPI0807790-8A patent/BRPI0807790B1/pt not_active IP Right Cessation
- 2008-02-22 CN CN200880012951A patent/CN101662951A/zh active Pending
-
2009
- 2009-09-14 ZA ZA2009/06390A patent/ZA200906390B/en unknown
- 2009-09-14 ZA ZA2009/06387A patent/ZA200906387B/en unknown
- 2009-09-14 ZA ZA2009/06389A patent/ZA200906389B/en unknown
- 2009-09-14 ZA ZA2009/06388A patent/ZA200906388B/en unknown
- 2009-11-30 ZA ZA2009/08481A patent/ZA200908481B/en unknown
-
2010
- 2010-09-07 US US12/876,451 patent/US9848622B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103315187A (zh) * | 2013-07-17 | 2013-09-25 | 江苏桂龙生物技术有限公司 | 一种预防宠物骨骼性疾病的饲料 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101662950A (zh) | 用于促进骨发育的组合物和方法 | |
| Majeed et al. | Limestone particle size, calcium and phosphorus levels, and phytase effects on live performance and nutrients digestibility of broilers | |
| CA2748979C (en) | Sodium stearoyl-2-lactylate derivatives as an animal feed additive for improving fat utilization efficiency | |
| Harper et al. | Clinical nutrition of small psittacines and passerines | |
| Cortés et al. | Identification and quantification of aflatoxins and aflatoxicol from poultry feed and their recovery in poultry litter | |
| CN102170792A (zh) | 提高老龄动物生活质量的方法 | |
| Alekseev et al. | The effect of the mineral supplement “Permait” and vitamin B13 on the productivity of broiler chickens | |
| Seyedalmoosavi et al. | Effects of increasing levels of whole Black Soldier Fly (Hermetia illucens) larvae in broiler rations on acceptance, nutrient and energy intakes and utilization, and growth performance of broilers | |
| WO1996035339A1 (fr) | COMPOSITION ALIMENTAIRE POUR ANIMAUX CONTENANT DE L'ACIDE POLY-η-GLUTAMIQUE | |
| US20180014556A1 (en) | Animal feed supplement composition | |
| US20230189845A1 (en) | Food compositions and methods for preventing copper-associated hepatopathies | |
| JP2008543287A (ja) | グルタミンを提供するための組成物および方法 | |
| EP2793609B1 (en) | Highly digestible pet food for improving stool quality | |
| Boerboom et al. | Dietary l-glutamic acid N, N-diacetic acid improves short-term maintenance of zinc homoeostasis in a model of subclinical zinc deficiency in weaned piglets | |
| Manopriya et al. | Importance of Phosphorus in Farm Animals | |
| US20200170282A1 (en) | Bird feed | |
| RU2822361C1 (ru) | Способ обогащения яиц кур йодом и селеном при одновременном увеличении яичной продуктивности | |
| Bordun et al. | Innovative approaches in the formation of compound feed recipes for decorative birds and singing birds and technology of compound feed production for them. | |
| RU2715671C1 (ru) | Кормовая добавка для молодняка крупного рогатого скота | |
| BR102022006531B1 (pt) | Uso de um emulsificante derivado do ácido ricinoleico para aumentar a absorção de cálcio e fósforo no trato digestivo de animais de produção | |
| Sohrabi et al. | Effects of dietary supplementation of guanidino acetic acid (GAA) and mating management methods on the performance of Ross 308 broiler breeders | |
| Kılınç et al. | Effects of addition of nettle seed meal to quail rations on performance and carcass characteristics | |
| RU2537555C2 (ru) | Корм сухой полнорационный для собак крупных пород сбалансированного аминокислотного состава с доказанными био-функциональными свойствами (варианты) | |
| Villaverde | Medical and nutritional issues with nutraceuticals. | |
| Mutucumarana1-z et al. | Measurement of Ileal and Excreta Endogenous Losses of Phosphorus in Broiler Chickens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20100303 |
|
| RJ01 | Rejection of invention patent application after publication |